Kirkland R T, Clayton G W
Pediatrics. 1979 Mar;63(3):386-8.
The availability of a commercial preparation of human growth hormone (hGH) prompted a study in children with hypopituitarism to determine the efficacy of a lower dose of hGH. Thirteen children, ages 4 years 3 months to 13 years 7 months, were given hGH concomitant with fluoxymesterone in an intermittent regimen. The hGH was given intramuscularly, 1 IU daily for 12 to 36 days in each course. There were four courses per year. The fluoxymesterone was given orally, 1 to 2 mg. The total amount of hGH administered was between 48 and 112 IU per year, as compared with the regimen of 312 IU per year, 2 units three times a week. The growth velocity in all 13 children improved, and the mean growth velocity was 6.4 cm +/- 1.13 SD. The mean bone age increment was 0.57 years +/- 0.14 SEM in one chronological year of therapy. The low dose regimen permits a significant reduction in cost of hGH without causing undue advance in bone age.
人生长激素（hGH）商业制剂的可得性促使了一项针对垂体功能减退儿童的研究，以确定较低剂量hGH的疗效。13名年龄在4岁3个月至13岁7个月的儿童，采用间歇性给药方案，接受hGH与氟甲睾酮联合治疗。hGH通过肌肉注射给药，每个疗程每日1国际单位，持续12至36天。每年进行四个疗程。氟甲睾酮口服给药，剂量为1至2毫克。与每周三次、每次2国际单位、每年312国际单位的给药方案相比，每年给予的hGH总量在48至112国际单位之间。所有13名儿童的生长速度均有所提高，平均生长速度为6.4厘米±1.13标准差。在一个自然年的治疗中，平均骨龄增加为0.57岁±0.14标准误。低剂量方案可显著降低hGH成本，且不会导致骨龄过度提前。
